These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
3. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G Digestion; 2016; 94(4):222-229. PubMed ID: 28030863 [TBL] [Abstract][Full Text] [Related]
4. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641 [TBL] [Abstract][Full Text] [Related]
5. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186 [TBL] [Abstract][Full Text] [Related]
6. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis. Hayuka K; Okuyama H; Murakami A; Okita Y; Nishiuchi T; Okano K; Suzuki Y; Tsuji A Chemotherapy; 2021; 66(3):58-64. PubMed ID: 34284397 [TBL] [Abstract][Full Text] [Related]
8. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140 [TBL] [Abstract][Full Text] [Related]
9. A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers. Wang Y; Camateros P; Cheung WY J Gastrointest Cancer; 2019 Mar; 50(1):62-68. PubMed ID: 29143916 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience. Zhang H; Kellett C; Lambert P; Kim CA Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907 [TBL] [Abstract][Full Text] [Related]
11. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029 [TBL] [Abstract][Full Text] [Related]
12. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641 [TBL] [Abstract][Full Text] [Related]
13. [Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit]. Hubault M; Faure R; Walter T; Forestier J; Lombard-Bohas C; Pivot C Bull Cancer; 2015 May; 102(5):403-4. PubMed ID: 25866372 [No Abstract] [Full Text] [Related]
14. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079 [TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Borazanci E; Von Hoff DD Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381 [TBL] [Abstract][Full Text] [Related]
16. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). Mizusawa J; Fukutomi A; Katayama H; Ishii H; Ioka T; Okusaka T; Ueno H; Ueno M; Ikeda M; Mizuno N; Ozaka M; Fukuda H; Furuse J; Pancreatology; 2018 Oct; 18(7):841-845. PubMed ID: 30075908 [TBL] [Abstract][Full Text] [Related]
18. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel. Surinach A; Phung T; Abdul-Rahim O; Khushman M Curr Oncol; 2020 Apr; 27(2):e222-e225. PubMed ID: 32489272 [TBL] [Abstract][Full Text] [Related]
19. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. Cui H; Guan J; Deng G; Yuan J; Lou C; Zhang W; Zhou A; Zhang Y; Zhou J; Dai G Med Sci Monit; 2020 Oct; 26():e927654. PubMed ID: 33100319 [TBL] [Abstract][Full Text] [Related]
20. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]